Patients
13.2 per 100,000 people
Suicide rate, Australia, 2023 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Australia Opioid Use Disorder Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Formulation, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$55.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $52.8 Mn | — | — |
| 2025 (base) | $56.9 Mn | +$4.1 Mn | — |
| 2026 (forecast) | $61.4 Mn | +$4.4 Mn | +7.8% |
| 2027 (forecast) | $66.2 Mn | +$4.8 Mn | +16.2% |
| 2028 (forecast) | $71.3 Mn | +$5.2 Mn | +25.3% |
| 2029 (forecast) | $76.9 Mn | +$5.6 Mn | +35% |
| 2030 (forecast) | $82.9 Mn | +$6.0 Mn | +45.6% |
| 2031 (forecast) | $89.4 Mn | +$6.5 Mn | +56.9% |
| 2032 (forecast) | $96.3 Mn | +$7.0 Mn | +69.2% |
| 2033 (forecast) | $103.8 Mn | +$7.5 Mn | +82.4% |
| 2034 (forecast) | $111.9 Mn | +$8.1 Mn | +96.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $56.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $111.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug, formulation and end user (see all) |
| Key players | Indivior, Alkermes, Orexo, Braeburn, Emergent BioSolutions (see all) |
| Regulator in Australia | TGASource: Therapeutic Goods Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Opioid use disorder drugs such as buprenorphine, methadone and naltrexone reduce cravings and overdose risk.
Key segments of the opioid Use Disorder Drugs market include drug (Buprenorphine, Methadone and Naltrexone) and formulation (Sublingual, Extended-Release Injectable and Implants).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the opioid Use Disorder Drugs market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the opioid Use Disorder Drugs market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the opioid Use Disorder Drugs market.
The opioid Use Disorder Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.[2] Suicide rate: 13.2 per 100,000 people in 2023, the latest WHO figure for Australia.[3]
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for opioid Use Disorder Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.
What doctors and scientists are doing in Opioid Use Disorder Drugs right now, from free public sources.
13.2 per 100,000 people
Suicide rate, Australia, 2023 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
From our blog
Australia · 1 shared keyword
Australia
Australia
Australia
Australia
Australia
OTC & Nutraceuticals · Australia
Digital Health · Australia
Digital Health · Australia
OTC & Nutraceuticals · Australia
Healthcare Services · Australia
Healthcare Services · Australia